June 14, 2007

Statement from U.S. Attorney Christopher J. Christie on Expiration of Deferred Prosecution Agreement with Bristol-Myers Squibb

Christopher J. Christie, U.S. Attorney for the District of New Jersey, announced today that the deferred prosecution agreement (DPA) between his office and Bristol-Myers Squibb will officially expire tomorrow, Friday, June 15, 2007.

The DPA will officially end with the dismissal of the criminal Complaint originally filed against Bristol-Myers Squibb in U.S. District Court for the District of New Jersey two years ago.

“Bristol-Myers Squibb has made significant and transformational changes in its compliance practices as a result of the DPA,” said Christie. “We promised that federal oversight would help to make BMS a better company. The objective facts prove that goal has been achieved.”

On June 15, 2005, Bristol-Myers Squibb announced that it had entered into a deferred prosecution agreement to resolve the investigation by the U.S. Attorney’s Office in New Jersey relating to wholesaler inventory and various accounting matters. The U.S. Attorney’s Office had agreed not to prosecute its filed criminal Complaint if the company complied with all of the terms of the DPA. The dismissal of the complaint is a result of the U.S. Attorney’s satisfaction that the company has complied in full with the terms of the DPA.

-end-